Antimicrobial benzothiophenes
A novel benzothiophene compound targets PBP2a and PBP4 in MRSA, addressing antibiotic resistance and preventing osteomyelitis by enhancing β-lactam antibiotic efficacy.
Patent Information
- Application Number
- PCT/US2026/027397
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Antibiotic resistance in Staphylococcus aureus, particularly methicillin-resistant strains (MRSA), poses a significant challenge due to the development of resistance mechanisms like PBP4, which complicates treatment of infections such as osteomyelitis, and current adjuvants only target β-lactamases.
Development of a novel chlorinated benzothiophene compound that inhibits essential penicillin binding proteins (PBP2a and PBP4) in MRSA, potentially restoring sensitivity to β-lactam antibiotics and preventing osteomyelitis.
The compound effectively reduces the minimum inhibitory concentration of oxacillin in MRSA strains and demonstrates potential as a therapeutic to treat MRSA infections and prevent osteomyelitis by targeting PBP2 and PBP4.
Smart Images

Figure US2026027397_12112026_PF_FP_ABST
Abstract
Description
[0001] ANTIMICROBIAL BENZOTHIOPHENES
[0002] RELATED APPLICATIONS
[0003] This application claims priority under 35 U. S. C. §119(e) to U.S. Provisional Patent Application No. 63 / 802,326, filed May 8, 2025, which is incorporated herein by reference.
[0004] GOVERNMENT SUPPORT
[0005] This invention was made with government support under AR072000 awarded by the National Institutes of Health. The government has certain rights in the invention.
[0006] BACKGROUND OF THE IN VENTION
[0007] Antibiotic resistance is a well-established global health threat. Staphylococcus aureus is one of the six ESKAPE pathogens (Enterococcus faecium. S. aureus. Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacter species), a group of pathogens notorious for their multidrug resistance (MDR). Although the introduction of new antibiotics has historically been employed to combat MDR threats, the rapid development of antibiotic resistance coupled with large pharmaceutical companies exit from antibiotic development has prompted the investigation into orthogonal approaches to address these resistant bacteria. One solution is through use of adjuvants, which are compounds that do not possess antimicrobial properties, but aid existing antibiotics by interrupting bacterial resistance mechanisms that render antibiotics inactive. The common example of an antibiotic adjuvant is the p-lactamase inhibitor clavulanic acid, which is paired with the P-lactam antibiotic amoxicillin. Currently, the only clinically approved adjuvants target p-lactamases; however, additional defense mechanisms that can be targeted in bacteria to overcome resistance.
[0008] Staphylococcus aureus is the main cause of osteomyelitis, a disease characterized by infection and inflammation of the bone. Osteomyelitis largely impacts individuals who are immobile or disabled, suffering with diabetes, and those who have experienced trauma that leads to exposed skin or reconstructive surgery. Treatment options for osteomyelitis are limited, intense, and typically resort to amputation. Osteomyelitis is characterized by the bacterial invasion of the cortical bone osteocyte lacuna-canalicular network (OLCN), which leads to chronic infection, and is characterized by frequent relapses in infection.
[0009] Penicillin binding proteins (PBPs) are transpeptidases that are responsible for cross-linking peptidoglycan to build the bacterial cell wall. Penicillin binding protein 4 (PBP4) is a low molecular weight PBP with transpeptidase activity. Multiple classes of PBPs are involved in resistance to p- lactams, however PBP4 has been observed to mediate resistance to ceftobiprole (BPR), a fifth
[0010] 1
[0011] 501.118WO1
[0012] ND P25-034-PCTgeneration β-lactam developed to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. Under most conditions, PBP4 is non-essential.
[0013] In S. aureus, the pbp4 gene encodes for the PBP enzyme, in turn mediating β-lactam resistance. Previously, a strain of MRSA with a pbp4 deletion was unable to colonize OLCNs. In vitro screenings using Microfiuidic-Silicon Membrane-Canalicular Arrays (uSiM-CA). which are devices with 500 nm pores that mimic the opening of canaliculi, determined that MRS A strains with a pbp4 deletion were unable to cross artificial pores, suggesting that PBP4 is essential for S. aureus to colonize OLCNs.
[0014] Accordingly, new compounds that target penicillin binding protein would be useful for combating bacterial infections and bacterial infections that, are resistant to current antibiotics.
[0015] SUMMARY
[0016] We have discovered a novel chlorinated benzothiophene that is a potent antimicrobial agent to Gram-positive bacteria with a majority of our data centered around Methicillin-Resistant Staphylococcus aureus (MRSA), The compound not only is active against MRSA strains but also is active against strains that are resistant to fifth-generation cephalosporins that were developed to treat MRSA infections. The compound inhibits essential penicillin binding proteins as well as the alternative penicillin binding protein PBP2a. The compound is useful for treatment of Staphylococcus infections and for other infections from Gram-positive bacteria.
[0017] Accordingly, this disclosure provides a compound of Formula I:
[0018] Heteroaryl-Amido (1),
[0019] wherein,
[0020] Heteroaryl is represented by Formula IA1, IA2, IA3, or 1A4:
[0021]
[0022] wherein,
[0023] each J1is S, O, or NRawherein Rais H or –(C1-C6)alkyl;
[0024] each J2is CRbwherein Rbis H or –(C1-C6)alkyl, or each J2is N;
[0025] each R1is H, halo, or –(C1-C6)alkyl;
[0026] each R1bis H, halo, or –(C1-C6)alkyl; and
[0027] each R2is H, halo, or –(C1-C6)alkyl;
[0028] Amido is represented by Formula IB1:
[0029] 501.118WO1
[0030] ND P25-034-PCT
[0031]
[0032] (IBi),
[0033] wherein,
[0034] Amin is heterocycloalkyl or N(Rc)2wherein each Rcis independently –(C1-C6)alkyl;
[0035] L is absent or NRcwherein Rcis H or –(C1-C6)alkyl;
[0036] R3is H or –(C1-C6)alkyl;
[0037] R4is H, halo, or unsubstituted or substituted –(C1-C6)alkyl; and
[0038] R5is H, halo, or –(C1-C6)alkyl;
[0039] or salt thereof.
[0040] This disclosure also provides a method for treating a bacterial infection comprising, administering a compound described herein to a subject in need thereof, wherein the bacterial inteclion is thereby treated.
[0041] The invention provides novel compounds of Formula I, intermediates for the synthesis of compounds of Formula I, as well as methods of preparing compounds of Formula I. The invention also provides compounds of Formula I that are useful as intermediates for the synthesis of other useful compounds. The invention provides for the use of compounds of Formula I for the manufacture of medicaments useful for the treatment of bacterial infections in a mammal, such as a human.
[0042] The invention provides for the use of the compounds described herein for use in medical therapy. The medical therapy can be treating a bacterial infection, including but not limited to a MRSA infection. The invention also provides for the use of a compound as described herein for the manufacture of a medicament to treat an infection in a mammal, for example, a MRSA in a human. The medicament can include a pharmaceutically acceptable diluent, excipient, or carrier.
[0043] BRIEF DESCRIPTION OF THE DRAWINGS
[0044] The following drawings form part of the specification and are included to further demonstrate certain embodiments or various aspects of the invention. In some instances, embodiments of the invention can be best understood by referring to the accompanying drawings in combination with the detailed description presented herein. The description and accompanying drawings may highlight a certain specific example, or a certain aspect of the invention. However, one skilled in the art will understand that portions of the example or aspect may be used in combination with other examples or aspects of the invention
[0045] 3
[0046] 501.118WO1
[0047] ND P25-034-PCTFigure 1. Growth curves for NDM-552. (1): Untreated MRSA 43300. (2): 1 μg / mL NDM-552. (3): 2 μg / mL NDM-552. (4): 4 μg / mL NDM-552. Data and SD from at least three replicates.
[0048] Figure 2. Murine wound infection model at 1 X. 2X, and 5X MIC of NDM-552. (1):
[0049] USA 300. (2): 1 pg / mL NDM-552. (3): 2 pg / mL NDM-552. (4): 5 ug / mL NDM-552. (5): 0.25 pg / mL ceftobiprole.
[0050] Figure 3. BOCILLIN-FL Binding assay of NDM-552. (4): PBP1. (5): PBP2. (2): PBP2a. (1): PBP3. (3): PBP4.
[0051] DETAILED DESCRIPTION
[0052] Exploration of a Benzothiophene Scaffold for Use as Adjuvants for β-Lactam Antibiotics against Methicillin Resistant Staphylococcus aureus.
[0053] Antibiotic resistance and the diminishing interest in antibiotic development creates a precedent for a future without treatments for bacterial infections. Penicillin binding protein 4 (PBP4) is a key determinant for resistance in methicillin-resistant Staphylococcus aureus (MRSA). PBP4 is essential for Staphylococcus aureus to infect the cortical bone osteocyte lacuna-canalicular network (OLCN), which causes osteomyelitis and creates a bacterial niche for recurring bone infection. Previously reported library screens identified compound 1. a benzothiophene-contaming compound, with putative PBP4 inhibitory activity. We uncovered a compound through a structure activity¬ relationship (SAR) study that lowers the minimum inhibitory concentration (MIC) of oxacillin 32-fold at 5 μM in oxacillin-resistant MRSA ATCC 1556. We show that the further development of a PBP4 inhibitor can function as both a therapeutic to prevent osteomyelitis and reverse PBP4-mediated P-lactam resistance.
[0054] Herein we report the optimization of parent compound 1, which revealed several compounds that act as putative PBP2a and PBP4 inhibitors. These compounds can be paired with beta lactam antibiotics to restore beta lactam sensitivity or be used prophylacticaily to prevent Osteomyelitis.
[0055] Chart 1. Structure of compound 1 depicting benzothiophene bead, phenyl core, and piperazine tail as ideal regions of structure activity relationship (SAR) exploration.
[0056]
[0057] Compound 1
[0058] Our discover efforts led to discovery of unexpected and potent antibacterial activity of benzothiophene NDM-552 against Staphylococcus aureus. Here, we report the gram-positive selecti ve antibacterial acti vity of NDM-552. Mechanism of action studies suggest that NDM-552 acts by targeting the essential penicillin binding protein 2 (PBP2).
[0059] 4
[0060] 501.118WO1
[0061] ND P25-034-PCTDefinitions.
[0062] The following definitions are included to provide a clear and consistent understanding of the specification and claims. As used herein, the recited terms have the following meanings All other terms and phrases used in this specification have their ordinary meanings as one of skill in the art would understand. Such ordinary meanings may be obtained by reference to technical dictionaries, such as Hawley’s Condensed Chemical Dictionary 14“ Edition, by R. J. Lewis, John Wiley & Sons, New York, N. Y., 2001.
[0063] References in the specification to "one embodiment", "an embodiment", etc., indicate that the embodiment described may include a particular aspect, feature, structure, moiety, or characteristic, but not every embodiment necessarily includes that aspect, feature, structure, moiety, or characteristic Moreover, such phrases may, but do not necessarily, refer to the same embodiment referred to in other portions of the specification. Further, when a particular aspect, feature, structure, moiety, or characteristic is described in connection with an embodiment, it is within the knowledge of one skilled in the art to affect or connect such aspect, feature, structure, moiety, or characteristic with other embodiments, whether or not explicitly described.
[0064] The singular forms "a," "an," and “the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a compound" includes a plurality of such compounds, so that a compound X includes a plurality of compounds X. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for the use of exclusive terminology, such as "solely," "only," and the like, in connection with any element described herein, and / or the recitation of claim elements or use of "negative” limitations.
[0065] The term "and / or" means any one of the items, any combination of the items, or all of the items with which this term is associated. The phrases "one or more" and "at least one” are readily understood by one of skill in the art., particularly when read in context of its usage. For example, the phrase can mean one, two, three, four, five, six, ten, 100. or any upper limit approximately 10, 100, or 1000 limes higher than a recited lower limit For example, one or more substituents on a phenyl ring refers to one to five, or one to four, for example if the phenyl ring is disubstituted
[0066] As will be understood by the skilled artisan, all numbers, including those expressing quantities of ingredients, properties such as molecular ’weight, reaction conditions, and so forth, are approximations and arc understood as being optionally modified in all instances by the term "about." These values can vary depending upon the desired properties sought to be obtained by those skilled in the art utilizing the teachings of the descriptions herein. It is also understood that such values inherently contain variability resulting from the standard deviations found in their respective testing measurements. When values are expressed as approximations, by use of the antecedent “about," it will be understood that the particular value without the modifier "about” also forms a further aspect 501.1 ISWOl
[0067] ND P25-034-PCTThe terms "about" and "approximately" are used interchangeably. Both terms can refer to a variation of ± 5%. ± 10%. ± 20%, or ± 25% of the value specified. For example, "about 50" percent can in some embodiments carry a variation from 45 to 55 percent, or as otherwise defined by a particular claim. For integer ranges, the term “about" can include one or two integers greater than and / or less than a recited integer at each end of the range. Unless indicated otherwise herein, the terms “about" and "approximately" are intended io include values, e.g., weight percentages, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, composition, or embodiment. The terms "about" and "approximately" can also modify the endpoints of a recited range as discussed above in tins paragraph
[0068] As will be understood by one skilled in the art, for any and ail purposes, particularly in terms of providing a written description, all ranges recited herein also encompass any and all possible sub¬ ranges and combinations of sub-ranges thereof, as well as the individual values making up the range, particularly integer values It is therefore understood that each unit between two particular units are also disclosed. For example, if 10 to 15 is disclosed, then 11, 12, 13, and 14 are also disclosed, individually, and as part of a range. A recited range (e.g, weight percentages or carbon groups) includes each specific value, integer, decimal, or identity within the range. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, or tenths As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will aiso be understood by one skilled in the art, all language such as "up to", "at least", "greater than", "less than”, "more than”, "or more", and the 1 ike, include the number recited and such terms refer to ranges that can be subsequently broken down into sub-ranges as discussed above. In the same manner. all ratios recited herein also include all sub-ratios falling within the broader ratio. Accordingly, specific values recited for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for radicals and substituents. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
[0069] This disclosure provides ranges, limits, and deviations to variables such as volume, mass, percentages, ratios, etc. It is understood by an ordinary person skilled in the art that a range, such as “number!” to “number2”, implies a continuous range of numbers that includes the whole numbers and fractional numbers. For example, 1 to 10 means 1, 2, 3, 4, 5.... 9, 10. It also means 1.0. 1.1, 1.2.
[0070] 1.3, … 9.8, 9.9, 10.0, and also means 1.01, 1.02, 1.03, and so on. if the variable disclosed is a number loss than “numberlO”, it implies a continuous range that includes whole numbers and fractional numbers less than number 10, as discussed above. Similarly, if the vanable disclosed is a number greater than “number 10”, it implies a continuous range that includes whole nu bers and
[0071] 6
[0072] 501.118WO1
[0073] ND P25-034-PCTfractional numbers greater than number 10. These ranges can be modified by the term “about’’, whose meaning has been described above.
[0074] The recitation of a), b), c)...or i). ii), iii), or the like in a list of components or steps do not confer any particular order unless explicitly stated.
[0075] One skilled in the art will also readily recognize that where members are grouped together in a common manner, such as in a Markush group, the invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group. Additionally, for all purposes, the invention encompasses not only the main group, but also the main group absent one or more of the group members. The invention therefore envisages the explicit exclusion of any one or more of members of a recited group. Accordingly, provisos may apply to any of the disclosed categories or embodiments whereby any one or more of tire recited elements, species, or embodiments, may be excluded from such categories or embodiments, for example, for use in an explicit negative limitation.
[0076] The term "contacting" refers to the act of touching. making contact, or of bringing to immediate or close proximity, including at the cellular or molecular level, for example, to bring about a physiological reaction, a chemical reaction, or a physical change, c.g., in a solution, in a reaction mixture, in vitro, or in vivo.
[0077] An "effective amount" refers to an amount effective to treat a disease, disorder, and / or condition, or io bring about a recited effect. For example, an effective amount can be an amount effective to reduce the progression or severity of the condition or symptoms being treated.
[0078] Detennination of a therapeutically effective amount is well w'ithin tire capacity of persons skilled in the ait. The term "effective amount" is intended to include an amount of a compound described herein, or an amount of a combination of compounds described herein, e.g. that is effective to treat or prevent a disease or disorder, or to treat the symptoms of the disease or disorder, in a host. Thus, an "effective amount" generally means an amount that provides the desired effect Alternatively, the terms "effective amount" or "therapeutically effective amount." as used herein, refer to a sufficient amount of an agent or a composition or combination of compositions being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The r esult can be reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective” amount in any individual case may be determined using techniques, such as a dose escalation study. The dose could be administered in one or more administrations. However, the precise determination of what would be considered an effective dose ay be based on factors individual to each patient, including, but not limited to, the patient's age, size, type or extent of 501.118WO1
[0079] ND P25-034-PCTdisease, stage of the disease, route of administration of the compositions, the type or extent of supplemental therapy used, ongoing disease process and type of treatment desired (e.g., aggressive vs. conventional treatment).
[0080] The terms "treating", "treat" and "treatment" include (i ) preventing a disease, pathologic or medical condition from occurring (e g, prophylaxis); (ii) inhibiting the disease, pathologic or medical condition or arresting its development; (iii) relieving the disease, pathologic or medical condition; and / or (iv) diminishing symptoms associated with the disease, pathologic or medical condition. Thus, tire terms "treat”, "treatment", and "treating" can extend to prophylaxis and can inciude prevent, prevention, preventing, lowering, stopping or reversing the progression or severity of the condition or symptoms being treated. As such, the term "treatment" ear- include medical, therapeutic, and / or prophylactic administration, as appropriate.
[0081] As used herein, "subject” or "patient” means an individual having symptoms of, or at risk for, a disease or other malignancy. A patient may he human or non-human and may include, for example, animal strains or species used as "model sy stems” for research purposes, such a mouse model as described herein Likewise, the patient may include either adults or juveniles (e.g., children).
[0082] Moreover, patient may mean any living organism, preferably a mammal (e.g., human or non-human) that may benefit from the administration of compositions contemplated herein. Examples of mammals include, but are not limited to, any member of die Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattie. horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to. birds, fish and the like, in one embodiment of the methods provided herein, the mammal is a human
[0083] As used herein, the terms “providing”. '‘administering,” “introducing,” are used interchangeably herein and refer to the placement of a compound of the disclosure into a subject by a method or route that results in at least partial localization of the compound to a desired site. The compound can be administered by any appropriate route that results in delivery to a desired location in the subject.
[0084] The compound and compositions described herein may be administered with additional compositions to prolong stability and activity of die compositions, or in combination with other therapeutic drugs.
[0085] The terms "inhibit”, "inhibiting", and "inhibition" refer to the slowing, halting, or reversing the growth or progression of a disease, infection, condition, or group of cells. The inhibition can be greater than about 20%, 40%, 60%, 80%, 90%, 95%, or 99%, for example, compared to the grovvtn or progression that occurs in the absence of the treatment or contacting.
[0086] 8
[0087] 501.118WOI
[0088] ND P25-034-PCTThe term “substantially" as used herein, is a broad term and is used in its ordinary sense, including, without limitation, being largely but not necessarily wholly that which is specified. For example, (he term could refer to a numerical value that may not be 100% the full numerical value. The full numerical value may be less by about 1%. about 2%, about 3%. about 4%, about 5%, about 6%. about 7%, about 8%, about 9%, about 10%, about 15%, or about 20%.
[0089] Wherever the term “comprising” is used herein, options are contemplated wherein the terms “consisting of' or “consisting essentially of’ are used instead. As used herein, “comprising” is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and docs not exclude additional, unrecited elements or method steps As used herein, "consisting of excludes any element, step, or ingredient not specified in the aspect element. As used herein, "consisting essentially of’ docs not exclude materials or steps that do not materially affect the basic and novel characteristics of the aspect. In each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of’ may be replaced with either of the other two terms. The disclosure illustratively described herein may be suitably practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.
[0090] This disclosure provides methods of making the compounds and compositions of the invention. The compounds and compositions can be prepared by any of the applicable techniques described herein, optionally in combination with standard techniques of organic synthesis. Many techniques such as etherification and esterification are well known in the art. However, many of these techniques are elaborated in Compendium of Organic Synthetic Methods (John Wiley & Sons, New York), Vol. 1, lan T. Harrison and Shuyen Harrison, 1971; Vol 2, Ian T. Harrison and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade, Jr.. 1980, Vol. 5, Leroy G. Wade. Jr, 1984; and Vol. 6; as well as standard organic reference texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Ed., by M. B. Smith and J. March (John Wiley & Sons, New York, 2001); Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modem Organic Chemistry. In 9 Volumes, Barty M. Trost. Editor-in-Chief (Pergamon Press, New York, 1993 printing); Advanced Organic Chemistry'. Part B: Reactions and Synthesis, Second Edition, Cary and Sundberg (1983); for heterocyclic synthesis see Hermanson, Greg T., Bioconjugate Techniques, Third Edition. Academic Press, 2013.
[0091] The formulas and compounds described herein can be modified using protecting groups. Suitable amino and carboxy protecting groups arc known to those skilled in the ait (sec lor example, Protecting Groups in Organic Synthesis, Second Edition, Greene, T. W., and Wuts, P. G. M., John Wiley & Sons, New York, and references cited therein; Philip J. Kocienski; Protecting Groups (Georg Thieme Verlag Stuttgart, New York, 1994), and references cited therein), and Comprehensive Organic Transformations, Larock, R. C.. Second Edition, John Wiley & Sons. New York ( 1 99), and referenced cited therein
[0092] 501.118WO1
[0093] ND P25-034-PCTThe term "halo" or "halide" refers to fluoro, chloro, bromo, or iodo. Similarly, the term "halogen" refers to fluorine, chlorine, bromine, and iodine.
[0094] The term "alkyl" refers to a branched or unbranched hydrocarbon having, for example, from 1-20 carbon atoms, and often 1- 12, 1-10, 1-8, 1 -6. or 1-4 carbon atoms: or for example, a range between 1-20 carbon atoms, such as 2-6, 3-6. 2-8, or 3-8 carbon atoms. As used herein, the term ‘"alkyl” also encompasses a -‘cycloalkyl”, defined below. Examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl (iso-propyl), 1 -butyl, 2-methyl-1-propyl (isobutyl), 2-butyl (sec-butyl), 2-methyl-2-propyl (t-butyl), 1 -pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3 -methyl- 1 -bu tyl, 2-methyl - 1 -butyl, 1 -hexyl, 2-hexy 1, 3-hexy 1, 2-methyi-2-pen tyl, 3 -methyl -2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, hexyl, octyl, decyl, dodecyl, and the like. The alkyl can be unsubstituted or substituted, for example, with a substituent described below or otherwise described herein. The alkyl can also be optionally partially or fully unsaturated. As such, the recitation of an alkyl group can include an alkenyl group or an alkynyl group. The alkyl can be a monovalent hydrocarbon radical, as described and exemplified above, or it can be a divalent hydrocarbon radical (i.e., an alkylene).
[0095] An alkylene is an alkyl group having two free valences at a carbon atom or two different carbon atoms of a carbon chain. Similarly, alkenylene and alk nylene are respectively an alkene and an alkyne having two free valences at two different carbon atoms, or an alkenylene can have the two free valences on the same carbon.
[0096] The term "cycloalkyl" refers to cyclic alkyl groups of, for example, from 3 to 10 carbon atoms having a single cyclic ring or multiple condensed rings. Cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantyl, and the like The cycloalkyl can be unsubstituted or substituted. The cycloalkyl group can be monovalent or divalent and can be optionally substituted as described for alkyl groups. The cycloalkyl group can optionally include one or more sites of unsaturation, for example, the cycloalkyl group can include one or more carbon-carbon double bonds, such as, for example, I -cyclopent- 1-enyl, l-cyclopent-2-enyi, l-cyclopent-3-enyl, cyclohexyl. 1- cyclohex-l-enyl, l-cyclohex-2-enyl, 1-cyclohex- 3-enyl, and die like.
[0097] The term ‘'heteroatom” refers to any atom in the periodic table that is not carbon or hydrogen. Typically, a heteroatom is 0, S, N, P, The heteroatom may also be a halogen, metal or metalloid.
[0098] The term "hctcrocycloalkyl” or ‘'hctcrocyclyl’’ refers io & saturated or partially saturated monocyclic, bicyclic, or polycyclic ring containing at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to 3 heteroatoms in at least one ring. Each ring is preferably from 3- to 10-membered. more preferably 4 to 7 membered. Examples of suitable heterocycloalkyl substituents include pyrrolidinyl. tetrahydrofuranyl, tetrahydrothiofuranyl. piperidinyl, piperazinyl,
[0099] 10
[0100] 501.118WO1
[0101] ND P25-034-PCTtetrahydropyranyl, morpholinyl, 1,3-diazapanyl, 1,4-diazapanyl. 1,4-oxazepanyl, and 1,4- oxaihiapanyl. The group may be a terminal group or a bridging group.
[0102] The term "aryl" refers to an aromatic hydrocarbon group derived from the removal of at least one hydrogen atom from a single carbon atom of a parent aromatic ring system. The radical attachment site can be at a saturated or unsaturated carbon atom of the parent ring system. The aryl group can have from 6 to 30 carbon atoms, for example, about 6-10 carbon atoms. The aryl group can have a single ring (e.g., phenyl) or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl). Typical aryl groups include, but are not limited to, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like. The aryl can be unsubstituted or optionally substituted with a substituent described below. For example, a phenyl moiety or group may be substituted with one or more substituents RAwhere RAis at the ortho-, meta-, or para-position, and X is an integer variable of 1 to 5.
[0103] The term "heteroaryl" refers to a monocyclic, bicyclic, or tricyclic ring system containing one. two, or three aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring. The heteroaryl can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, as described in the definition of "substituted". Typical heteroaryl groups contain 2-20 carbon atoms in the ring skeleton in addition to the one or more heteroatoms, wherein the ring skeleton comprises a 5-membered ring, a 6-membered ring, two 5-membered rings, two 6-membered rings, or a 5 -membered ring fused to a 6-membered ring.
[0104] Examples of heteroaryl groups include, but are not limited to, 2H-pyrrolyl, 3H-indolyl, 4H- quinolizinyl, acridinyl, benzo[b]thienyl, benzothiazolyl, P-carbolinyl, carbazolyl, chromenyl, cinnolinyl, dibenzo[b,d]furanyl, furazanyl, furyl, imidazolyl, imidizolyl, indazolyl. indolisinyl. indolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxazolyl, perimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl. phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thianthrenyl, thiazolyl, thienyl, triazolyl, tetrazolyl, and xanthenyl. In one embodiment the term "heteroaiyl” denotes a monocyclic aromatic ring containing five or six ring atoms containing carbon and 1, 2, 3, or 4 heteroatoms independently selected from non-peroxide oxygen, sulfur, andN(Z) wherein Z is absent or is H, O, alkyl, aryl, or (C₁-C₆)alkylaryl. In some embodiments, heteroaryl denotes an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benzo-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
[0105] As used herein, the term "substituted" or ‘’substituent” is intended to indicate that one or more (for example, in various embodiments. 1-10; in other embodiments, 1-6; in some embodiments 1, 2, 3, 4, or 5: in certain embodiments, 1, 2, or 3; and in other embodiments, 1 or 2) hydrogens on the 11
[0106] 501.11SWO1
[0107] ND P25-034-PCTgroup indicated in the expression using “substituted’’ (or “substituent”) is replaced with a selection from the indicated group(s). or with a suitable group known to those of skill in the art, provided that the indicated atom’s normal valency is not exceeded, and that the substitution results in a stable compound. Suitable indicated groups include, e.g., alkyl, alkenyl, alkynyl, alkoxy, haloalkyl. hydroxyalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkanoyi, alkoxycarbonyl, amino, alkylamino, dialkylamino, carboxyalkyl, alkylthio, alkylsulfinyl, and alkylsulfonyl. Substituents of the indicated groups can be those recited in a specific list of substituents described herein, or as one of skill in the art would recognize, can be one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyi, alkoxycarbonyl, amino, alkylamino, dialkylamino, trifluoromethylthio, difluoromethyl, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkyl thio, alkylsulfinyl, alkylsulfonyl, and cyano. Suitable substituents of indicated groups can be bonded to a substituted carbon atom include F, Cl, Br, I, OR', OC(O)N(R')₂, CN, CF₃, OCF₃, R', O, S, C(O), S(O), methylenediosy, ethylenedioxy, N(R')2, SR', SOR', SO2R'. SO₂N(R')₂, SO₃R', C(O)R', C(O)C(O)R’, C(O)CH2C(O)R’, C(S)R’, C(O)OR', OC(O)R’, C(O)N(R’)2, OC(O)N(R')2, C(S)N(R’)2, (CH₂)₀₋₂NHC(O)R, N(R')N(R')C(O)R', N(R’)N(R)C(O)OR’, N(R!)N(R‘)CON(Rfo, N(R‘)SO?. R’, N(R')SO₂N(R')₂, N(R')C(O)OR', N(R')C(O)R', N(R’)C(S)R', N(R’)C(O)N(R’)2, N(R’)C(S)N(R’)2, N(COR')COR‘, N(OR’)R'. C(=NH)N(R’)2, C(O)N(OR’)R', or C(=NOR')R' wherein R’ can be hydrogen or a carbon-based moiety (e.g., (C₁-C₆)alkyl), and wherein the carbon-based moiety can itself be further substituted. When a substituent is monovalent, such as, for example. F or Cl, it is bonded to the atom it is substituting by a single bond. When a substituent is divalent, such as 0, it is bonded to the atom it is substituting by a double bond; for example, a carbon atom substituted with O forms a carbonyl group. C=O.
[0108] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. The compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms, it is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof, such as racemic mixtures, which form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane- polarized light. In describing an optically active compound, the prefixes D and L, or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and I or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory For a given chemical structure, these stereoisomers are identical except that they are 12
[0109] 501.118WO1
[0110] ND P25-034-PCTmirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate (defined below), which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process
[0111] The term ‘’IC50” is generally defined as the concentration required to inhibit a specific biological or biochemical function by half, or to kill 50% of the cells in a designated time period, typically 24 hours.
[0112] Embodiments of the Technology.
[0113] 1. A compound of Formula I:
[0114] Heteroaryl–Amido (I),
[0115] herein.
[0116] Heteroaryl is represented by Formula IA1, IA2, IA3, or 1A4:
[0117]
[0118] wherein.
[0119] each J¹ is S, O, or NRᵃ wherein Rᵃ is H or –(C₁-C₆)alkyl;
[0120] each J² is CRᵇ wherein Rᵇ is H or –(C₁-C₆)alkyl, or each J² is N;
[0121] each R¹ is H, halo, or –(C₁-C₆)alkyl;
[0122] each R¹ᵇ is H, halo, or –(C₁-C₆)alkyl; and
[0123] each R² is H, halo, or –(C₁-C₆)alkyl;
[0124] Amido is represented by Formula IB1:
[0125]
[0126] wherein,
[0127] Amin is heterocycloalkyl or N(Rᶜ)₂ wherein each Rᶜ is independently –(C₁-C₆)alkyl;
[0128] L is absent or NRᶜ wherein Rᶜ is H or –(C₁-C₆)alkyl;
[0129] is II oi 11. i”t. 6 / <ilky I,
[0130] R⁴ is H, halo, or unsubstituted or substituted –(C₁-C₆)alkyl; and
[0131] R⁵ is H, halo, or –(C₁-C₆)alkyl;
[0132] 501.118WO1
[0133] ND P25-034-PCTor salt thereof
[0134] 2. The compound of embodiment 1, wherein the Heteroaryl moiety of Formula I is represented by Formula IA1.
[0135] 3. The compound of embodiment 2. wherein the Heteroaryl moiety represented by Formula IA1 is Formula IA5:
[0136]
[0137] wherein Rᵇ is H, halo, or –(C₁-C₆)alkyl.
[0138] 4. The compound of embodiment 3, wherein the Heteroaryl moiety represented by Formula IA5 is:
[0139]
[0140] 5. The compound of embodiment 1, wherein the Amido moiety of Formula 1 is represented by Formula 1B2:
[0141] Amin
[0142]
[0143] 6. The compound of any one of embodiments 1-5, wherein Amin is a 5- or 6-membered nitrogen-heterocycloalkyl.
[0144] 7 The compound of any one of embodiments 1-6, wherein Amin is piperidine, piperazine, morpholine, pyrrolidine, or dimethyl amine.
[0145] 8. The compound of any one of embodiments 1 -7, wherein Amin is:
[0146] In some e
[0147]
[0148] 9 The compound of any one of embodiments 1 -8, wherein R5is positioned ortho relative to R410 The compound of any one of embodiments 1-8, wherein R3is positioned
[0149]
[0150] relative to R4.
[0151] 11. The compound of any one of embodiments 1-8, wherein R⁵ is positioned para relative to R⁴.
[0152] 12. The compound of any one of embodiments 1-11, wherein R⁴ is H.
[0153] 13. The compound of any one of embodiments 1-12, wherein R⁵ is H.
[0154] 14 The compound of embodiment 1, wherein the compound is:
[0155] 14
[0156] 501.118WO1
[0157] ND P25-034-PCT
[0158]
[0159] 501.118WO1
[0160] ND E15. A method for treating a bacterial infection comprising, administering a compound of any one of embodiments 1-14 to a subject in need thereof, wherein the bacterial infection is thereby treated.
[0161] 16 The method of embodiment 15, wherein the bacterial infection is caused by Gram-positive bacteria.
[0162] 17. The method of embodiment 15 or 16, wherein the bacterial infection is caused by methicillin- resistant Staphylococcus aureus (MRS A).
[0163] 18. The method of embodiment 17, wherein the compound is active against a MRSA strain that is resistant to a cephalosporin.
[0164] 19. The method of any one of embodiments 15- 18, wherein the compound inhibits penicillin binding protein 4 (PBP4) and / or penicillin binding protein 2a (PBP2a).
[0165] 20. The method of any one of embodiments 15-19. wherein the compound is:
[0166]
[0167] or salt thereof.
[0168] Results and Discussion.
[0169] Initial compound synthesis & screening. We initiated the study by screening a 30,000- member library, which identified putative PBP4 inhibitor compound 1 (Chart 1 ). When dosed at 25 pM, 1 lowers the minimum inhibitory concentration (MIC) of BPR 16-fold in BPR-resistant. PBP4 over-expressor, S. aureus CRB. The same compound was investigated against a strain of MRSA that does not over-express PBP4. Compound 1 does not impact S. aureus PBP4 expression in USA300. implying that compound 1 has potential as a PBP4 inhibitor. To further investigate 1, we began by synthesizing a library of compounds with altered benzothiophene head groups, phenyl cores, and piperazine tails. The first set of compounds in this library were synthesized utilizing a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride mediated coupling with commercially available amines and carboxylic acids to yield products 2-13 (Scheme la,b)
[0170] Scheme 1a. General synthesis of benzothiophene analogs. Reagents and conditions for path A: (a) K₂CO₃, 1-methylpiperazine; (b) Pd / C (10%), H₂, MeOH, rt, 12 hr or SnCl₂, HCl; (c) appropriate benzothiophene-2- or benzothiophene-3-carboxylic acid, EDC, DMAP, DCM, rt, 24 h.
[0171]
[0172] 16
[0173] 501.118WO1
[0174] ND P25-034-PCTScheme 1b. General synthesis of benzothiophene analogs with commercially available anilines. (c) appropriate benzothiophene-2-carboxylic acid or benzothiophene-3-carboxylic acid, commercially available amine, EDC, DMAP, DCM, rt, 24 h.
[0175]
[0176] We first measured the standalone antibacterial activity of each compound against MRSA 1556. Compounds 1-10 and 12-13 return an MIC value >200 μM and compound 11 returns an MIC of 100 pM (Table 1). After determining compounds 2-13 do not possess significant standalone antibacterial activity, the same compounds were tested for their adjuvant activity against the same strain in combination with oxacillin. Parent compound 1 returns an oxacillin MIC value of 0.25 μg / mL when dosed at 7.5 μM which is eight-fold lower than the reported Clinical Laboratory Standards Institute (CLSI) breakpoint value of 2 μg / mL for oxacillin in MRSA, The breakpoint concentration is a utilized as measure of whether a strain of bacteria is susceptible or resistant to given conditions.
[0177] Compounds 4-7 and 10 return MIC values within two-fold of the oxacillin MIC against MRSA 1556, overall indicating a loss of adjuvant activity compared to the parent. Compounds 4-7 possess a thiophene, indole, furan, and naphthalene ring respectively, which provides insight that the benzothiophene moiety could be essential for activity. Compound 10, which includes a 5- chlorobenzothiophene is also inactive, which could indicate the five-position is electronically disfavored for PBP binding. Compounds 2 and 3 are isosteres of the benzothiophene present in the parent. Compound 2, which lacks a three-position substituent returns comparable activity to the parent at 7.5 pM. However, 3 returns a sub-breakpoint MIC value at 30 μM, which is lost when
[0178] 17
[0179] 501.118WO1
[0180] ND P25-034-PCTtested at 15 pM. Overall, the isosteres do not return the same activity as the parent indicating there is possibly an electronic effect involved in the potential binding of PBP2a.
[0181] Compound 8 returns an MIC value of 8 ug / mL at 60 pM, which is lost when tested at 30 pM. Given that oxacillin resistance is not completely restored, it is possible that substitutions at the six-position of the benzothiophene may have a minor impact on PBP binding. Compounds 9-13 have activity similar to the parent with MIC values ranging from 0.5 - 2 pg / mL. Compounds 9 and 13 have MIC values of 2 μg / mL at 7.5 and 5 μM, respectively (Table 1). Compound 13 lowers the MIC within the breakpoint value of oxacillin in MRSA 1556 at 5 μM, which is less than the active concentration of the parent compound.
[0182] Table 1. Standalone MIC and potentiation of oxacillin by head group analogs.
[0183]
[0184] Next, changes to the phenyl core and the piperazine core of the parent compound were investigated. Compounds 14 - 19. and 22 - 24 were synthesized via EDC-mediated coupling with commercially available carboxy lic acids and anilines. Compounds 20, 21, and 25 were synthesized utilizing a three-step approach. Commercially available 4-fluoronitrobenzenes were reacted with 1-methylpiperazine to yield various 1-methyl-4-(4-nitrophenyl)piperazines. Compounds 20 and 21 were reduced using 10% Pd / C and H₂ to produce their corresponding anilines. Compound 25 was reduced using tin(II)chloride to produce the aniline. The final anilines were then reacted with 3- chlorobenzothiophene-2-carboxylic acid and EDC to afford the final product.
[0185] Chart 3. Piperazine analogs
[0186]
[0187] 501.118WO1
[0188] ND P25-034-PCT
[0189]
[0190] Compounds 14 - 18 and 24 exhibit a complete loss of activity in combination with oxacillin returning MIC values of 32 μg / mL (Table 2). Compounds 14 through 16, which contain the most drastic piperazine tail changes, result in a loss of activity. Compound 17 exhibits higher standalone toxicity than other compounds tested with a compound only MIC of 12.5 μM. When compound 17 is combined with oxacillin at 30% this concentration (3.25 μM), no oxacillin potentiation activity is observed. Compound 18 contains a piperidine instead of a piperazine, which results in a loss of oxacillin potentiation activity. Compound 22 contains the piperazine tail in the para position compared to the unsubstituted aromatic ring, while compound 23 shifts the piperazine tail to the meta position with regards to the aromatic ring and compound 24 shifts the piperazine to the ortho position. Compound 23 lowers the MIC to sub-breakpoint levels at 30 μM, where 22 and 24 do not lower the oxacillin to breakpoint concentrations at the highest concentration tested (60 μM).
[0191] Compounds 21, and 25 display moderate activity at high concentrations. Compound 20 lowers the MIC to sub-breakpoint levels when dosed at 15 μM, however it does have a lower standalone MIC value compared to the parent compound. Compound 20 replaces the chlorine on the aniline core with a methyl isostere. This methyl group may interact with a 'wider range of PBPs thus resulting in antibacterial activity. Compound 19 has a lower standalone MIC value of 25 μM; however, in combination with oxacillin at 7.5 μM (the same concentration tested as the parent), the oxacillin MIC is lowered to 0.5 μg / mL. Compound 19 contains a methyl piperidine ring. Between 18 and 19, the N-methyl nitrogen seems to be vital for adjuvant activity.
[0192] 501.118WO1
[0193] ND P25-034-PCTTable 2. Standalone MIC and potentiation of oxacillin by piperazine tail analogs.
[0194]
[0195] After several compounds with varied tails and head groups were synthesized and tested, four anilines were chosen to be synthesized and tested with benzothiophene-2-carboxylic acid based on 5 their lack of activity with 3-chlorobenzothiophene-2-carboxylic acid (Chart 4). Overall, we hoped to uncover activity that was not previously detected with the 3-chloro equivalents or the following aniline groups.
[0196] Chart 4. Piperazine analogs 26 - 29
[0197]
[0198] Compound 26 maintains the same activity to compound 14 regardless of whether a chlorine or hydrogen is on the three-position of the benzothiophene (Table 3). It is possible that the missing portions of the piperazine rings contribute to activity and binding to PBP2a and the diamine in 26 and 14 might not conform to the binding pocket of PBP2a. Compound 27, which includes the morpholine ring has increased activity lowering the oxacillin MIC to the breakpoint. Compound 28 with the pyrrolidine ring shows increased activity' compared to its 3-chloro counterpart, but compared to the parent, the activity' is not improved. Finally, compound 29, with a para piperazine, returned a complete lack of activity.
[0199] 501.118WO1
[0200] ND P25-034-PCTTable 3. Standalone MIC and potentiation of oxacillin by analogs 26 - 29.
[0201]
[0202] Further strain testing. We tested compounds against two additional MRSA strains, MRSA ATCC 43300 and MRSA AH- 1263, to determine if their activity is broad spectrum or strain specific We uncovered that compounds 1, 2, 8, 9, 17, 19, and 20 lower the MIC below the oxacillin breakpoint against 43300 at concentrations ≤10 μM (Table 4) The activity of each compound shows that adjuvant activity for this library of compounds may not be strain specific (Table 4). As a result, compounds 1, 9, 13, and 17 each maintained sub-breakpoint activity in MRSA AH 1263 at concentrations comparable to the parent compound.
[0203]
[0204] Hybrid compound synthesis and testing. As a result of our initial biological screening. several hybrid compounds were synthesized. The aniline side chain of compound 19 was reacted with several head groups where augmented oxacillin activity was observed (Chart 5). Overall, we aim that the hybrid compounds will be additive in their activity.
[0205] Chart 5. Hybrid analogs 30 - 33.
[0206]
[0207] I! T. tiH 4., T.. t BA. i ".w" C "wys-" ->.yH
[0208] » -M M M
[0209] These four compounds were tested in combination with oxacillin against MRSA 1556, MRSA 43300, and MRSA AH- 1263 and consistently showed that compounds 30 and 33 lower the MIC within 2-fold of the breakpoint value at various concentrations. However, the most, promising combination(s) are compound 30 at 10 μM against MRSA 1556 and 33 at 10 μM in MRSA ATCC 43300 (Table 5).
[0210] Table 5. Standalone MIC and potentiation of hybrid compounds.
[0211]
[0212] All previous potentiation assays were tested with oxacillin as a way to predict adjuvant interaction or binding with PBP2a. As & result, several compounds were tested in another strain of 501.118WO1
[0213] ND P25-034-PCTMRSA, MRS CRB, which is a mecA negative and PBP4 over-expressing strain of MRSA. The mecA gene codes for the PBP2a protein and potentiation with CRB and ceflobiprole (BPR) was tested to determine if compounds potentially bind to PBP4.
[0214] Several compounds tested have comparable activity to the parent compound at lower concentrations, including compounds that potentially bind PBP4 (Table 6). Largely, this is important for dual activity of the desired adjuvant.
[0215] Table 6. Standalone MIC and potentiation of listed compounds with CRB and BPR.
[0216]
[0217] Compound NDM-552. NDM-552 was synthesized via a nucleophilic aromatic substitution reaction between commercially available 2-chI<-o-4-fluoro-l-niirobenzene and 1 -methylpiperazine to yield intermediate 2 (Scheme 1). Afterwards, a tin(ll)chloride reduction of the nitro group afforded the aniline 3, which was subsequently coupled with 3-chlorobenzothiophene-2-carbonyl chloride to generate NDM-552.
[0218] Scheme 2: Synthetic route to NDM-552. (a) K2CO3. 1 -methylpiperazine, DMF, 30 min 95.3% yield; (b) SnCl₂, HCl, EtOH, 80 °C, 1 hr. 92.7% yield; (c) 3-chlorobenzothiophene-2-carbonyl chloride, TEA, DCM, rt, 12 hr, 33.7 % yield
[0219]
[0220] Initial biological screening. First, we measured the standalone antibacterial activity of NDM-552 against a library of gram-positive bacterial strains, including MRSA, methicillin- susceptible. Si aureus. (MSSA) cystic fibrosis S. aureus (CFSA), Enterococcus faecium, and Staphylococcus epidermidis (Table 7). Each strain returned a minimum inhibitory concentration (MIC) of 1-2 μg / mL. The oxacillin MIC against MSSA ATCC 29213 is reported as 0.25 μg / mL.5The oxacillin MIC in commonly tested MRSA strains (MRSA 15556, 43300, 33591, BAA-44, BAA-
[0221] 501.118WO1
[0222] ND P25-034-PCT811, BAA- 1753, BAA-1770, BAA- 1685) range from 32 - 256 pg / mL, showing remarkably consistent activity among gram-positive bacteria.
[0223] Table 7. NDM-552 MICs against various gram-positive bacterial strains.
[0224]
[0225] We then examined activity against gram-negative bacterial species including K. pneumoniae, A. baumannii, and P. aeruginosa. The MIC of NDM-552 in wildtype KP2146, AB19606, AB17978, and PA01 is >16 μg / mL (highest concentration tested) (Table 8). It is predicted that the difference in MICs of NDM-552 between gram-negative and gram-positive strains is due to the differing bacterial cell walls. To hypothesize whether NDM-552 lacks the ability to enter gram-negative cell walls, the MIC against an LOS deficient A. baumannii strain, AB 17978 ΔLOS. NDM-552 returned an MIC of >16 μg / mL against LOS deficient AB 17978, implying that the lack of activity against gram-negative bacteria is likely related to target specificity, not the ability of NDM-552 to penetrate the cell wall. Another barrier for antibiotics is the presence of efflux pumps. To determine whether the lack of activity in gram-negative cells is attributable to rapid efflux, the MIC of NDM-552 was determined against a strain of A. baumannii that lacks the adeIJK genes that are known for encoding porin efflux pump system on the cell wall. The MIC of NDM-552 against AB 5075 ΔadeIJK was >16 μg / mL, implying that the lack of activity in gram-negative bacteria is not attributable to the rapid efflux of NDM-552.
[0226] 501.118WO1
[0227] ND P25-034-PCTTable 8. NDM-552 MICs against various gram-negative bacterial strains.
[0228]
[0229] Evaluation of NDM-552 MIC in the presence of Fetal Bovine Serum (FBS) and Triton-X Detergent. The MIC of NDM-552 was determined in the presence of a 9:1 ratio of cation-adjusted Mueller Hinton Broth (CAMHB): Fetal Bovine Serum (FBS). The addition of FBS into CAMHB used for MIC determination in MRSA ATCC 1556 led to a 16-fold increase in the MIC from 1 μg / mL to 16 μg / mL. The MIC was expected to increase due to the presence of additional proteins and lipids in vitro The MIC of NDM-552 was also determined in presence of 0.01% Triton-X in MRSA ATCC 1556 (Table 9). The addition of Triton-X, which is known to prevent protein denaturation, was tested to determine whether NDM-552 causes protein denaturation.6The MIC of NDM-552 remained at 1 pg / mL with the addition of 0.01% Triton-X. implying that NDM-552 does not denature protein.Table 9. MIC of NDM-552 in MRSA ATCC 1556 with and without addition of FBS and detergent.
[0230]
[0231] Gram-negative testing in combination with polymyxin B nonapeptide hydrochloride. NDM-552 was tested in K. pneumoniae in combination with polymyxin B nonapeptide hydrochloride (PMBN). PMBN is a cationic cyclic peptide derived by enzymatic processing from the naturally occurring peptide, polymyxin B.7, 8PMBN permeabilizes gram-negative outer membranes, allowing substrates to enter bacterial cells without killing bacterial ceils. When tested with varying concentrations of PMBN, the MIC of NDM-552 in KP 2146 did not change (Table 10). As a result, we can predict that the activity of NDM-552 for gram-positive bacteria is attributable to target specificity.
[0232] Table 10. MIC of NDM-552 in KP 2146 with various concentrations of PMBN
[0233]
[0234] 501.118WO1
[0235] ND P25-034-PCTEvaluation of NDM-552 Cytotoxicity & PK / PD Studies. To establish the therapeutic index (TI) of NDM-552, the compound's effect on viability of the hepatocellular carcinoma cell line, HepG2, was determined. The TI for conventional antibiotic development is defined as (mammalian cell CC50) / (antibiotic MIC), with a TI ≥50 desirable for further development. The CC50value of NDM-552 against HepG2 cells is 141.8 μM, an active concentration between 1 – 2 μg / mL (2.19 – 4.38 μM), and a TI ranging from 32.37 – 64.75. NDM-552 was assessed for metabolic stability in mouse S9 fractions, and for stability in mouse plasma. After four hours, NDM-552 returned a high plasma stability (88.2%), and the internal clearance of the compound was very high (224 mL / min / kg). Finally, the microsomal half-life of NDM-552 is 5.93 minutes.
[0236] Table 11. Initial pharmacokinetic and eukaryotic toxicity data
[0237]
[0238] Time-kill studies of NDM-552. A growth curve was constructed for NDM-552 using MRSA 43300 as a representative strain (Figure 1). NDM-552 was examined at its MIC (1 μg / mL), along with 2X and 4X this concentration. Based on the changes in colony forming units (CFUs), the NDM- 552 was determined to be bacteriostatic against MRSA 43300 at all concentrations tested.
[0239] Evolution of Resistance to NDM-552 and identification of Mutated Genes in Evolved Strains. To determine the rate of resistance acquisition and gain insight into resistance mechanisms to NDM- 552 MRSA ATCC BAA-1556 was serially passaged in the presence of 0.25X. 0.5X. IX, 2X. and 4X the MIC of NDM-552 over ten days. MICs were recorded every second day for eight days (Table 12) Resistance in the bacterial population serially passaged with NDM-552 increased, ending with an MIC >64 μg / mL.
[0240] Table 12. MIC of NDM-552 every second day of evolution experiment.
[0241]
[0242] Adjuvant Activity with Evolved MRSA ATCC 1556. We determined whether NDM-552 possesses oxacillin adjuvant activity against the evolved NDM-552 resistant MRSA strain and found that NDM-552 lowers the oxacillin MIC from 64 μg / mL to 0.125 μg / mL at 2 μg / mL (Table 13).
[0243] 501.118WO1
[0244] ND P25-034-PCTTable 13. Potentiation of oxacillin (OX) by NDM-552 in evolved MRSA ATCC 1556.
[0245]
[0246] To determine if the potentiation activity is specific to oxacillin, we tested NDM-552 (2 μg / mL) with other classes of antibiotics that are resistant to the evolved ATCC MRSA 1556 strain. The MIC of azithromycin and bacitracin remained unchanged, while the tetracycline MIC decreased four-fold (Table 14). The oxacillin specific adjuvant activity may be a result of the target of NDM- 552 playing a role in oxacillin resistance.
[0247] Table 14. Potentiation of azithromycin (AZ), bacitracin (BAC), and tetracycline (TET) with 2 μg / mL of NDM-552 in the evolved ATCC MRSA 1556 strain.
[0248]
[0249] Frequency of Resistance. To quantify the rate of resistance emergence, we performed spontaneous frequency of resistance (FoR) studies using MRSA ATCC BA -1556 using standard Luria-Delbruck Fluctuation conditions. NDM-552 displayed a FoR of 2.39 X IO'9at 8X the MIC (8 pg / ml.<). Oxacillin frequency of resistance in MSS is reported to be 1 O’6at 2 pg / ml. oxacillin. hi vivo activity. Murine Wound Model. The activity of NDM-552 in a murine wound infection model was examined. There is a statistically significant decrease in bacterial burden of the wound following treatment with 1 pg / mL NDM-552. In addition, the decrease in bacterial burden at 2 μg / mL and 5 μg / mL is comparable to the bacterial burden following treatment with 0.25 μg / mL ceftobiprole, the positive control.
[0250] 501.118WO1
[0251] ND P25-034-PCTBOCILLIN-FL Binding Assay. To determine relative binding of NDM-552 to PBP1, PBP2, PBP2a, PBP3, and PBP4, we performed a BOCILLIN-FL binding assay in which binding to recombinant PBPs was evaluated using a BODIPY labeled penicillin. The percentage inhibition of BOCILLIN-FL binding is shown in Figure 3. NDM-552 binds more strongly to PBP2 compared to other PBPs. A downside to the BOCILLIN-FL assay is that the assay measures noncovalent ligand to inhibit binding of a covalent substrate. Therefore, this assay only allows for a qualitative comparison of the efficacy among lead compounds tested.
[0252] Microscale Thermophoresis (MST) Binding.
[0253] Table 15. Binding profiles Kn(pM) values determined from MST.
[0254] Compound | Relative Binding (IC₅₀) (μg / mL) for respective PBPs
[0255]
[0256] NDM-552 | 404.7 | 35.0 | 907.0 | 2464 | 559.1 We used microscale thermophoresis (MST) to quantify binding of NDM-552 to purified PBPs from COL. The KDs of NDM-552 for each protein are shown in Table 15. NDM-552 showed strongest binding to PBP2 (KD= 12.3 ± 8.52) and PBP4 (KD= 12.00 ± 9.12) and moderate binding to PBP2a (KD= 37.83 ± 20.26).
[0257] Table 16. Binding profiles KD(μM) values determined from MST
[0258]
[0259] PBP 4 Potentiation activity. To predict if NDM-552 inhibits PBP4 in a cell based assay, it was tested for potentiation of the fifth-generation cephalosporin, ceftobiprole (BPR) in CRB. a mecA negative (gene encoding for PBP2a), PBP4 over-expressor. Resistance to cephalosporin antibiotics, which overcome resistance mediated by PBP2a, is mediated by non-essential PBP4. It was found that at half of its active concentration in CRB, NDM-552 potentiates BPR to its antibiotic breakpoint of 2 pg / mL in MRSA (Table 16).
[0260] Table 17. Potentiation of ceftobiprole (BPR) with 0.5 pg / mL of NDM-552 CRB.
[0261]
[0262] 501.118WO1
[0263] ND P25-034-PCTMoenomycin data. A popular PBP2 inhibitor of transglycosylation is known as moenomycin, flavomycin, or bambermycin. This phosphoglycolipid class of antibiotics. A moenomycin resistant strain of COL was generated: Moenomycin MIC in COL - 0.5 pg / mL, Moenomycin resistant strain MIC = 2.
[0264] Scheme 1: (a) N-methyl piperazine, K₂CO₃, DMF. (b) SnCl₂, EtOH, 80 °C, 12 hr. (c) (1): 3-chlorobenzothiophene-2-carboxylic acid, TEA, DCM, 12 hr. (2): TFA, DCM.
[0265]
[0266] Table 18. NDM-673 MICs (μg / mL) against select MRSA bacterial strains
[0267]
[0268] Table 19. Pharmacokinetic parameters for select compounds.
[0269]
[0270] Table 20. MST data for NDM-669 and NDM-673 against PBP2 and PBP4. (KDin μM).
[0271]
[0272] Conclusion.
[0273] In this study, we identify and characterize NDM-552, a novel benzothiophene-containing compound with potent and selective activity against gram-positive bacteria. Time-kill analyses demonstrate that NDM-552 is bacteriostatic, and cytotoxicity studies reveal a favorable therapeutic index that supports continued evaluation as an antibacterial lead. Mechanistic investigations implicate PBP2 as the primary’ target of NDM-552. Binding studies using BOC1LL IN-FL competition assays and MST revealed preferential binding to PBP2, and some additional affinity for PBP4. We predict that NDM-552 inhibits PBP2 transglycosylation activity due to its unique functionality and necessity for cell survival. NDM-552 shows significant efficacy in a murine wound infection model, achieving
[0274] 501.118WO1
[0275] ND P25-034-PCTbacterial burden reductions that are comparable to ceftobiprole. This work expands the chemical space of PBP2 inhibitors and provides a strong foundation for further optimization of NDM-552. Pharmaceutical Formulations.
[0276] The compounds described herein can be used to prepare therapeutic pharmaceutical compositions, for example, by combining the compounds with a pharmaceutically acceptable diluent, excipient, or carrier The compounds may be added to a carrier in the form of a salt or solvate For example, tn cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids that form a physiologically acceptable anion, for example, tosylate. methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, a-ketoglutarate, and P-glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, halide, sulfate, nitrate, bicarbonate, and carbonate salts.
[0277] Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid to provide a physiologically acceptable ionic compound. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example, calcium) salts of carboxylic acids can also be prepared by analogous methods.
[0278] The compounds of the formulas described herein can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient, in a variety of forms. The forms can be specifically adapted to a chosen route of administration, e.g., oral or parenteral administration, by intravenous, intramuscular, topical or subcutaneous routes.
[0279] The compounds described herein may be systemically administered in combination with a pharmaceutically acceptable vehicle, such as an inert diluent or an assimilable edible earner. For oral administration, compounds can be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly into the food of a patient's diet. Compounds may also be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches. capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations typically contain at least 0.1% of active compound. The percentage of tire compositions and preparations can vary and may conveniently be from about 0.5% to about 60%, about 1% to about 25%, or about 2% to about 10%. of the weight of a given unit dosage form. The amount of active compound in such therapeutically usefol compositions can be such that an effective dosage level can be obtained.
[0280] The tablets, troches, pills, capsules, and the like may also contain one or more of the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as
[0281] 30
[0282] 501.118WO1
[0283] ND P25-034-PCTdicalci am phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like: and a lubricant such as magnesium stearate. A sweetening agent such as sucrose, fructose, lactose or aspartame; or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring, may be added. When the unit dosage form is a capsule. it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and flavoring such as cherry or orange flavor. Any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
[0284] The active compound may be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can be prepared in glycerol, liquid polyethylene glycols, triacetin, or mixtures thereof, or in a pharmaceutically acceptable oil. Under ordinary’ conditions of storage and use, preparations may contain a preservative to prevent the growth of microorganisms.
[0285] Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions, dispersions, or sterile powders comprising the active ingredient adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. The ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions, or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and / or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by agents delaying absorption, for example, aluminum monostearate and / or gelatin.
[0286] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, optionally followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation can include vacuum drying and freeze drying
[0287] 31
[0288] 501.1 ISWO1
[0289] ND P25-034-PCTtechniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the solution.
[0290] For topical administration, compounds may be applied in pure form, e.g, when they are liquids. However, it will generally be desirable to administer the active agent to the skin as a composition or formulation, for example, in combination with a dermatologically acceptable carrier, which may be a solid, a liquid, a gel, or the like.
[0291] Usefill solid carriers include finely divided solids such as talc, clay, microctystalline cellulose, silica, alumina, and the like. Useful liquid carriers include water, dimethyl sulfoxide (DMSO), alcohols, glycols, or water-alcohol / glycol blends, in which a compound can be dissolved or dispersed at effective levels, optionally with die aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using a pump-type or aerosol sprayer.
[0292] Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses, or modified mineral materials can also be employed wiih liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
[0293] Examples of dermatological compositions for delivering active agents to the skin are known to the art: for example, see U.S. Patent Nos. 4,992,478 (Geria), 4,820,508 (Wortzman), 4,608,392 (Jacquet et al.), and 4,559,157 (Smith et al.). Such dermatological compositions can be used in combinations with the compounds described herein where an ingredient of such compositions can optionally be replaced by a compound described herein, or a compound described herein can be added to the composition.
[0294] Useful dosages of the compounds described herein can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Patent No. 4,938,949 (Borch et al.). The amount of a compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular compound or salt selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will be ultimately at the discretion of an attendant physician or clinician.
[0295] In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg / kg, e.g., from about 10 to about 75 mg / kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day. preferably in the range of 6 to 90 mg / kg / day, most preferably in the range of 15 to 60 mg / kg / day.
[0296] The compound is conveniently formulated in unit dosage form: for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently. 50 to 500 mg of active ingredient per unit
[0297] 32
[0298] 501.1 ISWO1
[0299] ND P25-034-PCTdosage form. In one embodiment, the invention provides a composition comprising a compound of the invention formulated in such a unit dosage form
[0300] The compound can be conveniently administered in a unit dosage form, for example, containing 5 to 1000 mg / m2, conveniently 10 to 750 mg / m2, most conveniently, 50 to 500 mg / m2of active ingredient per unit dosage form. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
[0301] The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g,. into a number of discrete loosely spaced administrations: such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
[0302] The compounds described herein can be effective antibiotic adjuvants and have higher potency and / or reduced toxicity as compared to an antibiotic alone.
[0303] The invention provides therapeutic methods of treating a MRSA infection in a mammal, which involve administering to a mammal having a MRSA infection an effective amount, of a compound or composition described herein. A mammal includes a primate, human, rodent, canine, feline, bovine, ovine, equine, swine, caprine, bovine and the like.
[0304] The abi lity of a compound of the invention to treat a MRSA infection may be determined by using assays well known to the art. For example, the design of treatment protocols, toxicity evaluation, data analysis, quantification of bacteria ceil kill are known In addition, ability of a compound to treat a MRSA infection may be determined using the Tests as described below.
[0305] The following Examples are intended to illustrate the above invention and should not be construed as to narrow its scope. One skilled in the art will readily recognize that the Examples suggest many other ways in which the invention could be practiced. It should be understood that numerous variations and modifications may be made while remaining within the scope of the invention.
[0306] EXAMPLES
[0307] Example 1 Experimental
[0308] While preparing derivatives of compounds such as the compounds described above, a different class of related compounds that have Gram-positive antibacterial activity was discovered. The compound shown in Table 21 was shown to be active against several strains of infectious bacteria.
[0309] 501.118WO1
[0310] ND P25-034-PCTTable 21. Activity Data for 3-chloro-N-(2-chloro-4-(4-methylpiperazin-1-yl)phenyl)benzo[b]thiophene-2-carboxamide:
[0311]
[0312]
[0313] Example 2. Pharmaceutical Dosage Forms.
[0314] The following formulations illustrate representative pharmaceutical dosage forms that may be used for the therapeutic or prophylactic administration of a compound of a formula described herein, a compound specifically disclosed herein, or a pharmaceutically acceptable salt or solvate thereof (hereinafter referred to as 'Compound Xs):
[0315] (i) Tablet 1 mg / tablet
[0316] 'Compound X’ 100.0
[0317] Lactose 77.5
[0318] 34
[0319] 501.118WO1
[0320] ND P25-034-PCTPovidone 15.0 Croscarmellose sodium 12.0 Microcrystalline cellulose 92.5 Magnesium stearate 3.0
[0321] 300.0(ii) Tablet 2 mg / tablet 'Compound X' 20 0 Microcrystalline cellulose 410.0 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 5.0
[0322] 500.0
[0323]
[0324] Colloidal silicon dioxide 1.5 Lactose 465.5 Pregelatinized starch 120.0 Magnesium stearate 3.0
[0325] 600.0 Li:v]...l< Oecppa^[ J. Jilc / rnLl mg / mL 'Compound X' (free acid form) 1.0 Dibasic sodium phosphate 12.0 Monobasic sodium phosphate 0.7 Sodium chloride 4.5
[0326] 1.0 N Sodium hydroxide solution q.s
[0327] (pH adjustment to 7.0-7.5)
[0328] Water for injection q.s ad 1 mL (v) Injection 2 (10 mg / mL) mg / niL 'Compound X’ (free acid form) 10 0 Monobasic sodium phosphate 0.3 Dibasic sodium phosphate 1.1 Polyethylene glycol 400 200.0
[0329] 0.1 N Sodium hydroxide solution q.s
[0330] (pH adjustment to 7.0-7.5)
[0331] Water for injection q.s. ad 1 mL
[0332]
[0333] Oleic acid 10 Trichloromonofluoromethane 5,000 Dichlorodifluoromethane 10,000 Dichlorotetrafluoroethane 5.000 (vii) Topical Gel 1 wt.% 'Compound X' 5% Carbomer 934 1.25% Triethanolamine q.s. 501.118WO1
[0334] ND P25-034-PCT(pH adjustment to 5-7)
[0335] Methyl paraben 0.2%
[0336] Purified water q.s. to 100g
[0337] %
[0338]
[0339] Methylcellulose 2%
[0340] Methyl paraben 0.2%
[0341] Propyl paraben 0.02%
[0342] Purified water q.s. to 100g
[0343] wt_%
[0344]
[0345] Propylene glycol 1%
[0346] Anhydrous ointment base 40%
[0347] Polysorbate 80 XO,<
[0348] Methyl paraben 0.2%,
[0349] Purified water q.s. to 100g
[0350] (x) Topical Cream 1 wt.%
[0351] 'Compound X'
[0352]
[0353] White bees wax 10%
[0354] Liquid paraffin 30%
[0355] Benzyl alcohol 5%
[0356] Purified water q.s. to 100g
[0357] (xi) Topical Cream 2 wt.%
[0358] 'Compound X' 5%
[0359] Stearic acid 10%
[0360] Glyceryl monostearate
[0361] Polyoxyethylene stearyl ether
[0362] Sorbitol 5%
[0363] Isopropyl palmitate 2%
[0364] Methyl Paraben 0.2%
[0365] Purified water q.s. to 100g
[0366] These formulations ay be prepared by conventional procedures well known in the pharmaceutical art. It will be appreciated that the above pharmaceutical compositions may be varied according to well-known pharmaceutical techniques to accommodate differing amounts and types of active ingredient ‘Compound X'. Aerosol formulation (vi) may be used in conjunction with a standard, metered dose aerosol dispenser Additionally, the specific ingredients and proportions are for illustrative purposes. Ingredients may be exchanged for suitable equivalents and proportions may be varied, according to the desired properties of the dosage form of interest.
[0367] All publications, patents, and patent documents cited herein are incorporated by reference as though individually incorporated by reference. No limitations inconsistent with this disclosure are to be understood therefrom The invention has been described with reference to various specific and 36
[0368] 501.118WO1
[0369] ND P25-034-PCTpreferred embodiments and techniques. However, many variations and modifications may be made while remaining within the spirit and scope of the invention.
[0370] While specific embodiments have been described above with reference to the disclosed embodiments and examples, such embodiments are only illustrative and do not limit the scope of the invention. Changes and modifications can he made in accordance with ordinary skill in the art without departing from the invention in its broader aspects as defined in the following claims.
[0371] 37
[0372] 501.118WO1
[0373] ND P25-034-PCT
Claims
What is claimed is:1 A compound of Formula I:Heteroaryl–Amido (I),wherein.Heteroaryl is represented by Formula IA1, IA2, IA3, or IA4.wherein.each J1is S, O, or NRawherein Rais H or - (G-G>)alkyheach J2is CRbwherein Rbis H or –(C1-C6)alkyl, or each J2is N;each R1is H, halo, or –(C1-C6)alkyl;each Rlbis H, halo,each R2is H, halo, or –(C1-C6)alkyl;Amido is represented by Formula IB1:ZP P4Cl Amin (IB1),wherein.Amin is heterocycloalkyl or N(Rc)2wherein each Rcis independently –(C1-C6)alkyl; L is absent or NRcwherein Rcis H or –(C1-C6)alkyl,R’ is H or - (C I’Cgialkyl;R4is H, halo, or unsubstituted or substituted –(C1-C6)alkyl; andR5is H, halo, or –(C1-C6)alkyl;or salt thereofThe compound of claim 1, wherein the Heteroaryl moiety of Formula I is represented by Formula IA1.The compound of claim 2, wherein the Heteroaryl moiety represented by Formula IA1 is Formula IA5:wherein Rbis H, halo, or –(C1-C6)alkyl.38501.118WO1ND P25-034-PCTThe compound of claim 3, wherein the Heteroaryl moiety represented by Formula IA5 is:
5. The compound of claim 1, wherein the Amido moiety of Formula I is represented by Formula IB2:
6. The compound of any one of claims 1-5, wherein Amin is a 5- or 6-membered nitrogen-heterocycloalkyl.
7. The compound of any one of claims 1-5, wherein Amin is piperidine, piperazine, morpholine, pyrrolidine, or dimethylamine.8 The compound of any one of claims 1-5, wherein Amin is:
9. The compound of any one of claims 1-5, wherein R’’ is positioned ortho relative to R4.
10. The compound of any one of claims 1-5. wherein R5is positioned meta relative to R4.
11. The compound of any one of claims 1-8, wherein R5is positioned para relative to R4.
12. The compound of any one of claims 1-5, wherein R4is H.
13. The compound of any one of claims 1-5, wherein R5is H.501.118WO1ND P25-034-PCT501.118WO1ND P25-034-PCT15. A method for treating a bacterial infection comprising, administering a compound of claim 1 to a subject in need thereof, wherein the bacterial infection is thereby treated.
16. The method of claim 15. wherein the bacterial infection is caused by Gram-positive bacteria.
17. The method of claim 15 or 16, wherein the bacterial infection is caused by methicillin- resistant Staphylococcus aureus (MRSA).
18. The method of claim 17, wherein the compound is active against a MRSA strain that is resistant to a cephalosporin.19 The method of claim 15. wherein the compound inhibits penicillin binding protein 4 (PBP4) and / or penicillin binding protein 2a (PBP2a).20 The method of claim 15, wherein the compound is:or salt thereof501.118WO1ND P25-034-PCT
